Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double‐blind placebo‐controlled trial
Authors' conclusion
This study shows that PM is metabolically active and reduces MGO, AGEs, sVCAM-1 and sICAM-1, but does not affect insulin sensitivity and vascular function in abdominally obese individuals. The reduction in adhesion markers is promising because these are important in the pathogenesis of endothelial damage and atherosclerosis.
Study context
- Population
- Abdominally obese individuals (54% female; mean age 50 years; mean BMI 32 kg/m²)
- Participants
- 36 / 36 / 36
- Comparison
- Pyridoxamine 25 mg or 200 mg vs placebo for 8 weeks
- Placebon = 36reference
- 25 mg pyridoxamine (PM)n = 36
- 200 mg PMn = 36
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Glycation, metabolic and vascular measurements · 8 weeks
- Reduced plasma methylglyoxal (MGO) and protein-bound MG-H1 with 200 mg PM vs placebo
- Reduced sVCAM-1 with 25 mg and 200 mg PM vs placebo
- Reduced sICAM-1 with 200 mg PM vs placebo
- No treatment effects on insulin sensitivity, vascular function or other functional outcomes
Original publication
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double‐blind placebo‐controlled trial. Diabetes Obes Metab. Published 14 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →